Vizgen laid off an undisclosed number of employees as part of a strategic reorganization, the company said without detailing impacted roles. In communications, Vizgen tied the change to investing in neuro discovery in academia and biopharma, while using partners for functions such as manufacturing to complement its strengths. The restructure follows a $48 million fundraise in January aimed at commercial expansion and pipeline execution, and continues a pattern of prior reorganizations in 2023 and 2024.